Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William F Dall'Acqua

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Methods (San Diego, Calif.)|April 26, 2005
Humanized antibodies and their applicationsHerren Wu, William F Dall'Acqua
Advances in Experimental Medicine and Biology|September 19, 2020
Emerging Strategies for Therapeutic Antibody Discovery from Human B CellsSaravanan Rajan, William F Dall'Acqua
Human Vaccines & Immunotherapeutics|July 20, 2016
Immunotherapies against antibiotics-resistant Klebsiella pneumoniaeXiaodong Xiao, Herren Wu, William F Dall'Acqua
The Journal of Biological Chemistry|June 24, 2006
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)William F Dall'Acqua, Peter A Kiener, Herren Wu
Plos One|November 6, 2014
Bi-epitope SPR surfaces: a solution to develop robust immunoassaysLi Peng, Melissa M Damschroder, Herren Wu, et al.
Acta Crystallographica. Section D, Biological Crystallography|June 19, 2008
Structural characterization of a human Fc fragment engineered for lack of effector functionsVaheh Oganesyan, Changshou Gao, Lena Shirinian, et al.
Molecular Immunology|December 15, 2007
Structural characterization of a mutated, ADCC-enhanced human Fc fragmentVaheh Oganesyan, Melissa M Damschroder, William Leach, et al.
Mabs|January 22, 2015
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibodyLi Peng, Vaheh Oganesyan, Herren Wu, et al.
Journal of Molecular Biology|August 27, 2011
Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibodyLi Peng, Vaheh Oganesyan, Melissa M Damschroder, et al.
The Journal of Biological Chemistry|May 1, 2015
Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody SifalimumabVaheh Oganesyan, Li Peng, Robert M Woods, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Methods (San Diego, Calif.)|April 26, 2005
Humanized antibodies and their applicationsHerren Wu, William F Dall'Acqua
Advances in Experimental Medicine and Biology|September 19, 2020
Emerging Strategies for Therapeutic Antibody Discovery from Human B CellsSaravanan Rajan, William F Dall'Acqua
Human Vaccines & Immunotherapeutics|July 20, 2016
Immunotherapies against antibiotics-resistant Klebsiella pneumoniaeXiaodong Xiao, Herren Wu, William F Dall'Acqua
The Journal of Biological Chemistry|June 24, 2006
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)William F Dall'Acqua, Peter A Kiener, Herren Wu
Plos One|November 6, 2014
Bi-epitope SPR surfaces: a solution to develop robust immunoassaysLi Peng, Melissa M Damschroder, Herren Wu, et al.
Acta Crystallographica. Section D, Biological Crystallography|June 19, 2008
Structural characterization of a human Fc fragment engineered for lack of effector functionsVaheh Oganesyan, Changshou Gao, Lena Shirinian, et al.
Molecular Immunology|December 15, 2007
Structural characterization of a mutated, ADCC-enhanced human Fc fragmentVaheh Oganesyan, Melissa M Damschroder, William Leach, et al.
Mabs|January 22, 2015
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibodyLi Peng, Vaheh Oganesyan, Herren Wu, et al.
Journal of Molecular Biology|August 27, 2011
Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibodyLi Peng, Vaheh Oganesyan, Melissa M Damschroder, et al.
The Journal of Biological Chemistry|May 1, 2015
Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody SifalimumabVaheh Oganesyan, Li Peng, Robert M Woods, et al.
Pageof 6